Summary Estimates were made of the rates at which cancer cells were released directly into the renal vein in patients undergoing radical nephrectomy for primary renal cancer. Cancer cells were counted in blood samples taken from the renal vein using a density gradient centrifugation procedure, and identified using immunocytochemical techniques, on the basis of their cytoskeletal intermediate filament proteins. Cancer cells were released as single cells and multicell emboli in 8/10 patients, in numbers varying widely between 14-7509 emboli ml -of blood. Despite a calculated median input into the metastatic process of 3.7 x I07 cancer cells per day for at least 180 days, only 3/10 patients had extraperitoneal metastases prior to surgery and only of the remaining disease-free patients subsequently developed distant metastases over a maximum 35 month period. These results are discussed in terms of primary tumour kinetics and metastatic inefficiency.
Animal studies in which cancer cells are introduced into the circulation via i.v. injections have shown that many malignant cells are required to produce relatively few tumour nodules in the lungs (Warren & Gates, 1936; Zeidman et al., 1950) . Other studies, in which the numbers of cancer cells shed spontaneously into the bloodstream from solid tumours were monitored by means of bioassay  or direct counting procedures (Liotta et al., 1974; Butler & Gullino, 1975; Glaves, 1983a) , also indicate that the numbers of malignant cells potentially seeded into an organ may be orders of magnitude more than the numbers of spontaneous metastases which subsequently develop. These findings and others have given rise to the concept of 'metastatic inefficiency' (Weiss, 1980; 1986) .
In contrast to the animal studies, there are very few reliable estimates of cancer cell input into the metastatic cascade in humans. Although many attempts were made to estimate the release of cancer cells into the bloodstream in the decade following Engell's pioneering studies (Engell, 1955) , many of these estimates were unreliable because of various methodologic problems associated with cancer cell isolation, deterioration, identification and enumeration, as discussed elsewhere (Nadel, 1965; Salsbury, 1975) . In addition, in many of these earlier studies, samples of peripheral blood were taken from antecubital veins, resulting in underestimates of the total numbers of circulating cancer cells since the vast majority of them would have been trapped in pulmonary capillaries before reaching this segment of the circulation.
As reliable estimates of circulating cells are required to gauge the overall efficiency of the metastatic process in humans, we have attempted to avoid the difficulties encountered in earlier investigations. Thus, cancer cells were isolated using a previously developed, efficient density gradient separation procedure (Glaves, 1983a) , and we have avoided organ-trapping artifacts, by direct blood-sampling from the renal vein, in patients undergoing radical nephrectomy for primary renal cancer.
Materials and methods
Blood samples Blood samples of 3-0 ml from 10 patients were collected into 10ml syringes containing 1000 (Glaves, 1983a (Glaves, 1983a) .
Indirect immunofluorescence assays of recovered cancer cells As previously described, a mouse monoclonal antibody (AE3) against keratins (Cooper et al., 1985) was used in indirect immunofluorescence assays performed for detection of circulating mouse carcinoma cells (Glaves et al., 1986 nephrectomy, fixed in 95% ethanol and embedded in paraffin at low (56°C) temperature.
Results
Confirmation of the reactivity of AE3 antibody with renal carcinoma cells is illustrated in Figure 1 which shows the results of indirect immunofluorescence assays with carcinoma tissue from patient KT-1. Stromal cells are not stained since they are of mesenchymal origin and express vimentin as their major intermediate filament protein (Lazarides, 1980) . Both single cancer cell emboli and multicell emboli were detected in blood samples taken from renal veins, as illustrated in Figure 1 , and a summary of the numbers of cancer cell emboli recovered is given in Table I . Disseminating cancer cells were present in 8/10 patients and as few as 14 emboli per ml blood were detected, although there were wide variations in the numbers of circulating emboli between individual patients. Multicell emboli comprised of 2 to over 15 cells were present in 5 of the 8 patients with detectable cells in their renal venous effluent; independent studies have shown that the cancer cell separation procedures used here does not result in the disproportionate loss or gain of cell clumps (Glaves, 1983a) .
The extent of metastasis in each patient was clinically assessed before and during the operation, at which time the assay for circulating cancer cells was made. Subsequent metastatic status was assessed during patient follow-up visits or at autopsy. Only 3 patients had clinically detectable extraperitoneal metastases prior to assay and 5 patients remained overtly disease-free for up to 35 months (Table I) .
Discussion
Patients with renal adenocarcinomas were selected since, unlike tumours at many other sites, the venous effluent is usually restricted to a single renal vein, and since average renal blood flow rates of 500 ml min-through each kidney have been documented (Altman & Dittmer, 1971) (Lazarides, 1980) which could conceivably be mistaken for cancer cells. Although examination of fixed material does not permit evaluation of cancer cell viability, animal studies involving both direct counts of cancer cells and their bioassay (Glaves, 1983a; , indicate that the majority of cells freshly released into major blood vessels may well be viable and potentially tumorigenic. In connection with tumorigenicity, it is important to note that in those patients with disseminating cancer emboli, as many as 20% were multicellular and experimental animal studies indicate that clumps of cancer cells are more efficient in generating metastases than equivalent numbers of single cancer cells (Fidler, 1973; Liotta et al., 1976) . Studies with experimental animal tumours indicate that 70-95% of cancer cells given by tail vein injection are arrested in the first downstream capillary bed, the pulmonary microvasculature (Fidler, 1970; Glaves, 1980) . The vast majority of those cancer cells arrested in the lungs are rapidly killed due to a variety of mechanical (Sato et al., 1976; Weiss, 1987) and host mediated (Riccardi et al., 1979; Glaves, 1983b) factors, with the net result that subtumorigenic doses of cancer cells are delivered to other organs (Weiss, 1980) . Such aspects of cancer cell delivery have been held to account for the metastatic patterns of several cancers, including kidney carcinomas (Weiss, 1985) , in which arterial metastases in other organs are more likely to occur in the presence of lung metastases which constitute generalizing sites and act as a source of disseminating cancer cells.
In order to determine the efficiency of that part of the process whereby (pulmonary) metastases are generated by circulating cancer cells, numerical estimates are required of both cancer cell input and metastasis formation. Our approach has been to calculate the tumour load in the lungs under conditions of 100% efficiency, when every cancer cell delivered was tumorigenic, and to compare this estimate with clinical observations. We have taken an admittedly simplistic view of tumour kinetics, in which in the absence of more detailed data it is assumed that cancer cells proliferate in an exponential manner without loss. The degree of inaccuracy of these assumptions is fully discussed by Steel (1977a) and others. On the basis of a 60-day doubling time (Steel, 1977b) and our stated assumptions, it would take 180 days for a 5cm diameter carcinoma which is the smallest in our series, to grow into a 10cm lesion which is the largest. The present studies indicate that lesions in this size range release 3.7 x 107 cancer cells per 24h into the renal vein, according to pro-rated cancer cell counts from Table I . Therefore, a total of -7 x 109 cells would have been released during the 180 day doubling period (i.e., 180 x 3.7 x 107). However, this may well be an underestimate because cancer cells may be released into the venous system by tumours considerably less than 5 cm diameter including occult primary lesions (Glaves, 1983a) . Median cell counts are used, since analogous experiments with mice (Glaves, 1983; (Glaves, 1983) . These latter results were based on direct observations, and did not involve use of calculations of tumour kinetics. Accordingly, following i.m. injection of 105 melanoma cells into groups of mice, counts of circulating cancer cells, recovered from blood samples taken from the right ventricle, were obtained from the time of injection to the maximum survival time of 35 days. Circulating cancer cells were detected from day 3 through day 35, and over this period a median of 2.4 x 107 melanoma cells was released into the blood. On examination of lungs under a dissection microscope, where lesions of 0.1 mm diameter can be detected, only between 0 to 1 lesion per mouse was detected. Thus, the efficiency of this, observed, part of the metastatic process was less than 10-7. A corresponding value of 10-6 was obtained for Lewis lung carcinomas in mice. Metastatic inefficiency of human cancer also was observed in other studies (Tarin et al., 1984) on patients with malignant ascites, in whom peritoneovenous shunts were used to alleviate abdominal distension so that patients effectively received autotransfusions of cancer cells over periods of weeks. Distant metastases were not detected in 8/15 of these patients although only one patient survived longer than 9 months.
Studies on the kinetics of solid tumour indicate that cell loss is a common feature of growing cell populations (Steel, 1977c) . Cell loss is partly due to cell death and partly to release of cancer cells from the primary lesions. Cell loss is usually measured indirectly by morphologic examination or inferred from discrepancies between rates of cell division and the size of the total population. However, the present studies provide a quantitative estimate of oine specific component of cell loss, that due to release by intravasation; in the case of a 10cm diameter spheroidal tumour (KT-6, Table I ) with an approximate volume of 150ml, only 0.04ml (=3.7 x 107) of cancer cells are released per day, corresponding to a daily loss by intravasation of -0.03%.
Although measurements of cancer cell intravasation are conceptually simple, reliable quantitative data of this type upon which kinetics of metastasis in human cancers can be based, have previously not been available.
